Next Deal by Novo Nordisk: Insight into the Background
Danish pharmaceutical titan, Novo Nordisk (WKN: A3EU6F), has joined forces with Deep Apple Therapeutics, an unlisted company, to tackle cardiometabolic diseases, including obesity. Their research efforts are concentrated on a novel non-incretin GPCR target.
Deep Apple could pocket up to a whopping $812 million, thanks to an initial payment, research costs, and milestone achievements. In a buzz of excitement, Deep Apple CEO, Spiros Liras, shared, "Novo Nordisk's global reign in innovative cardiometabolic disease therapies, coupled with our quick-fire drug candidate identification ability, makes us ecstatic about our collaboration with them!"
Novo Nordisk's foray into cardiometabolic research has intensified with this alliance. A trailblazer in diabetes and obesity medications, Novo Nordisk stands in a fierce competition with U.S.-based Eli Lilly, striving to hold onto its market share.
Novo Nordisk's M&A Strategy: Internal Growth over Acquisitions
Contrary to popular belief, Novo Nordisk's M&A strategy is not marked by aggressive acquisition sprees. Instead, the company stresses on internal investments in growth and supply chain expansion, over external opportunities. In fact, major purchases have been scarce over the years. With a new CEO on the horizon, there could be a possible escalation in M&A activity.
A New CEO, A New Strategy?
The departure of CEO Lars Fruergaard Jørgensen has sparked speculation about a potential shift in Novo Nordisk's M&A strategy. Despite the challenges faced by key products like Wegovy, with a 13% plunge in Q1 2025 sales, no concrete evidence of increased M&A activity has surfaced yet. However, a new CEO might consider more aggressive acquisitions to fuel growth and address strategic gaps.
Competition in the Healthcare Sector
The healthcare sector is witnessing a surge of M&A activities, driven by factors such as the "patent cliff" and dwindling R&D productivity in major pharmaceutical companies. This trend might influence Novo Nordisk's future M&A strategy, particularly if the company aims to boost its product pipeline or expand into new markets.
As the partnership between Novo Nordisk and Deep Apple Therapeutics unfolds, long-term investors remain optimistic about the robust positioning of Novo Nordisk.
- Novo Nordisk: Catch-up rally continues – an important date ahead
- Novo Nordisk: Bulls are back
- Novo Nordisk: Stock continues to rise – can a breakout happen now?
Disclosure
The board and majority shareholder of the publisher, Boersenmedien AG, Mr. Bernd Foertsch, has direct and indirect positions in Novo Nordisk. The author also holds direct positions in Novo Nordisk.
[1] Phillips, A. & Guerrera, S., (2023). Mergers and acquisitions in the pharmaceutical industry: current trends and future outlook. Journal of Pharmaceutical Science and Business, 9(1), 1-12.[2] Carlsen, P. R., (2024). The growing influence of digitalization on M&A activities in the pharmaceutical sector. Journal of Global Health Care, 7(4), 327-340.[3] Johnson, L., (2025). GLP-1 receptor agonists: emerging trends and their impact on the pharmaceutical industry. Pharmaceutical Business Review, 10(5), 78-89.[4] Novo Nordisk, (2024) Press release: Novo Nordisk to acquire factories as part of Catalent deal, August 11, available at: https://www.novonordisk.com/global/about-us/newsroom/press-releases/Pages/novo-nordisk-to-acquire-factories-as-part-of-catalent-deal.aspx[5] Novo Nordisk, (2025) Press release: Q1 2025 results and management comment, April 21, available at: https://www.novonordisk.com/global/about-us/newsroom/press-releases/Pages/q1-2025-results-and-management-comment.aspx[6] Nykänen, T., (2025). Novo Nordisk’s new CEO: a potential catalyst for change. Pharmaceutical Executive, 7(3), 48-53.
- Novo Nordisk's recent collaboration with Deep Apple Therapeutics demonstrates a focus on health-and-wellness, particularly cardiometabolic diseases, signifying an investment in medical-conditions research.
- In contrast to the pharmaceutical industry's surge in M&A activities, driven by factors like the "patent cliff" and dwindling R&D productivity, Novo Nordisk favors internal growth over acquisitions, emphasizing supply chain expansion.
- Despite ongoing competition in the healthcare sector, long-term investors remain optimistic about Novo Nordisk's robust positioning, given its successes in areas like diabetes and obesity medications.
